AI powered Biotech startup Peptilogics secured $35.4 Million

Peptilogics, a Pittsburgh-based clinical-stage biotechnology company has now secured $35.4 million in a Series B funding round.

Peptilogics is founded by Jonathan Steckbeck in the year 2013. It combines proven drug development expertise with the proprietary Artificial Intelligence and Machine Learning methods to find new connections among the diverse biomedical data across the entire drug development spectrum to map a new universe of the peptide sequences.

Jonathan Steckbeck, Ph.D., MBA, Founder, and CEO of Peptilogics, said, "We are thrilled to have the support of this visionary investor syndicate to accelerate our growth. Our goal is to enable the industry by unlocking the full potential of peptides through the development of technologies that facilitate the rapid design of more effective therapeutics."

Presight Capital co-founder Christian Angermayer, said, "We are building the world’s leading discovery and development platform for peptides, as we believe some of the world’s most impactful medicines in the future will be peptides."

The round was backed by the Presight Capital, with participation from Founders Fund and Peter Thiel.

The company as of now has plans to use the new funds to expand its computational platform and invest in technologies to improve its drug design engine.